Sheng Xiaoyan, Yang Shuiyuan, Wen Xiaomin, Zhang Xin, Ye Yongfeng, Zhao Peng, Zang Limin, Peng Kang, Du Enming, Li Sai
Nursing Department, Integrated Hospital of Traditional Chinese Medicine, Southern Medical University, Guangzhou, 510315, Guangdong, China.
Department of Pharmacy, Guangdong Second Provincial General Hospital, Guangzhou, 510317, Guangdong, China.
Chin Med. 2021 Feb 6;16(1):18. doi: 10.1186/s13020-021-00429-y.
Shende'an tablet (SDA) is a newly capsuled Chinese herbal formula derived from the Chinese traditional medicine Zhengan Xifeng Decoction which is approved for the treatment of neurasthenia and insomnia in China. This study aimed to investigate the neuroprotective effects of SDA against Parkinson's disease (PD) in vitro and in vivo.
In the present work, the neuroprotective effects and mechanism of SDA were evaluated in the cellular PD model. Male C57BL/6J mice were subject to a partial MPTP lesion alongside treatment with SDA. Behavioural test and tyrosine-hydroxylase immunohistochemistry were used to evaluate nigrostriatal tract integrity. HPLC analysis and Western blotting were used to assess the effect of SDA on dopamine metabolism and the expression of HO-1, PGC-1α and Nrf2, respectively.
Our results demonstrated that SDA had neuroprotective effect in dopaminergic PC12 cells with 6-OHDA lesion. It had also displayed efficient dopaminergic neuronal protection and motor behavior alleviation properties in MPTP-induced PD mice. In the PC12 cells and MPTP-induced Parkinson's disease animal models, SDA was highly efficacious in α-synuclein clearance associated with the activation of PGC-1α/Nrf2 signal pathway.
SDA demonstrated potential as a future therapeutic modality in PD through protecting dopamine neurons and alleviating the motor symptoms, mediated by the activation of PGC-1α/Nrf2 signal pathway.
神得安片（SDA）是一种新研制的胶囊剂型中药配方，源自中药镇肝熄风汤，在中国被批准用于治疗神经衰弱和失眠。本研究旨在探讨SDA在体外和体内对帕金森病（PD）的神经保护作用。
在本研究中，在细胞性PD模型中评估了SDA的神经保护作用及其机制。雄性C57BL/6J小鼠接受部分MPTP损伤并同时用SDA治疗。采用行为测试和酪氨酸羟化酶免疫组织化学法评估黑质纹状体通路的完整性。分别用高效液相色谱分析和蛋白质印迹法评估SDA对多巴胺代谢以及HO-1、PGC-1α和Nrf2表达的影响。
我们的结果表明，SDA对6-OHDA损伤的多巴胺能PC12细胞具有神经保护作用。在MPTP诱导的PD小鼠中，它还表现出有效的多巴胺能神经元保护和运动行为改善特性。在PC12细胞和MPTP诱导的帕金森病动物模型中，SDA在与PGC-1α/Nrf2信号通路激活相关的α-突触核蛋白清除方面非常有效。
SDA通过激活PGC-1α/Nrf2信号通路保护多巴胺神经元并减轻运动症状，显示出作为未来PD治疗方式的潜力。
